Pfizer is looking to newer products and acquisitions to offset a declining Covid business.
16hon MSN
Pfizer's 6.5% dividend yield looked too good to be true -- but management just silenced the skeptics
Is Pfizer a yield trap? No way.
Pfizer’s $2.3 billion bet on Trillium Therapeutics doesn’t look like it will ever pay out, with the Big Pharma abandoning the ...
By Mariam Sunny and Christy Santhosh May 5 (Reuters) - Pfizer reported higher-than-expected sales and profit on Tuesday and ...
Pfizer is also demonstrating that its commercial portfolio can flourish beyond the historically mammoth sales of its COVID-19 ...
By Mariam Sunny and Christy Santhosh May 5 (Reuters) - Pfizer said on Tuesday that it expects to return to stronger growth ...
Shares of Pfizer are down 50% from their 2021 high, and the yield is an alluring 6.4%.
Pharma giant is working hard to offset its post-Covid hangover but faces a patent cliff on many top-selling medicines ...
Veppanu, the first PROTAC therapy approved by the FDA, improved progression free survival by 43% versus AstraZeneca’s ...
Pfizer's vaccine business cooled off, and it is on its back foot in the GLP-1 race, but don't count the drug giant out.
Matthew Herper covers medical innovation — both its promise and its perils. Pfizer CEO Albert Bourla on Wednesday defended the development of Covid vaccinations, including Pfizer’s own, suggesting ...
Lyme disease is an illness caused by bacteria most commonly spread to humans from ticks. It can cause arthritis, muscle weakness and pain.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results